Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gascon

Showing results (21-30 of 96) with videos related to

Pageof 10
Sort By:
Science (New York, N.Y.)|December 11, 1981
Type III hyperlipoproteinemia associated with apolipoprotein E deficiencyG Ghiselli, E J Schaefer, P Gascon, et al.
American Journal of Obstetrics and Gynecology|July 1, 1992
Idiopathic myelofibrosis in pregnancy: a case report and review of the literatureU B Taylor, A D Bardeguez, N Iglesias, et al.
Haematologica|May 3, 2001
Epidemic hemolytic-uremic syndrome related to bleomycinS Albiol, J J Grau, A Pereira, et al.
Science (New York, N.Y.)|January 28, 1977
Endogenous opiate receptor ligand: electrically induced release in the guinea pig ileumM M Puig, P Gascon, G L Craviso, et al.
Cutis|April 1, 1991
Sign of Leser-Trélat with a metastatic mucinous adenocarcinomaR A Schwartz, M E Helmold, C K Janniger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1985
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivoN C Zoumbos, P Gascon, J Y Djeu, et al.
Thrombosis and Haemostasis|May 1, 1997
The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6E K Kruithof, J C Mestries, M P Gascon, et al.
Blood|September 1, 1986
Biological and immunological characterization of ATG and ALGE L Raefsky, P Gascon, A Gratwohl, et al.
Leukemia|November 1, 1988
A rare restriction enzyme site polymorphism in the breakpoint cluster region (bcr) of chromosome 22P Benn, A Grossman, L Soper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyK Blackwell, P Gascon, A Krendyukov, et al.
Pageof 10

Showing results (21-30 of 96) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|December 11, 1981
Type III hyperlipoproteinemia associated with apolipoprotein E deficiencyG Ghiselli, E J Schaefer, P Gascon, et al.
American Journal of Obstetrics and Gynecology|July 1, 1992
Idiopathic myelofibrosis in pregnancy: a case report and review of the literatureU B Taylor, A D Bardeguez, N Iglesias, et al.
Haematologica|May 3, 2001
Epidemic hemolytic-uremic syndrome related to bleomycinS Albiol, J J Grau, A Pereira, et al.
Science (New York, N.Y.)|January 28, 1977
Endogenous opiate receptor ligand: electrically induced release in the guinea pig ileumM M Puig, P Gascon, G L Craviso, et al.
Cutis|April 1, 1991
Sign of Leser-Trélat with a metastatic mucinous adenocarcinomaR A Schwartz, M E Helmold, C K Janniger, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1985
Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivoN C Zoumbos, P Gascon, J Y Djeu, et al.
Thrombosis and Haemostasis|May 1, 1997
The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6E K Kruithof, J C Mestries, M P Gascon, et al.
Blood|September 1, 1986
Biological and immunological characterization of ATG and ALGE L Raefsky, P Gascon, A Gratwohl, et al.
Leukemia|November 1, 1988
A rare restriction enzyme site polymorphism in the breakpoint cluster region (bcr) of chromosome 22P Benn, A Grossman, L Soper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2017
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapyK Blackwell, P Gascon, A Krendyukov, et al.
Pageof 10